# A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

> **NCT04908514** · PHASE2 · COMPLETED · sponsor: **Aldeyra Therapeutics, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** ADX-629

## Key facts

- **NCT ID:** NCT04908514
- **Lead sponsor:** Aldeyra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-07
- **Primary completion:** 2022-01-21
- **Final completion:** 2022-01-21
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908514, "A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04908514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*